| 4.67 -2.06 (-30.61%) | 05-15 14:46 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.63 |
1-year : | 7.93 |
| Resists | First : | 5.67 |
Second : | 6.78 |
| Pivot price | 5.65 |
|||
| Supports | First : | 3.88 |
Second : | 3.22 |
| MAs | MA(5) : | 6 |
MA(20) : | 5.6 |
| MA(100) : | 8.93 |
MA(250) : | 10.62 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1  |
| %K %D | K(14,3) : | 73.7 |
D(3) : | 86.9 |
| RSI | RSI(14): 42.6 |
|||
| 52-week | High : | 17.94 | Low : | 3.34 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AARD ] has closed above bottom band by 8.1%. Bollinger Bands are 49.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 30 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.79 - 6.81 | 6.81 - 6.84 |
| Low: | 6.06 - 6.09 | 6.09 - 6.11 |
| Close: | 6.68 - 6.72 | 6.72 - 6.76 |
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
Fri, 15 May 2026
Aardvark Therapeutics, Inc. - Common Stock (Nasdaq:AARD) Stock Quote - The Chronicle-Journal
Mon, 11 May 2026
AARD Stock Price, Quote & Chart | AARDVARK THERAPEUTICS INC (NASDAQ:AARD) - ChartMill
Thu, 07 May 2026
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman - Barchart.com
Thu, 07 May 2026
Trial pauses hit Aardvark Therapeutics (NASDAQ: AARD) as losses and R&D spending climb - Stock Titan
Tue, 24 Mar 2026
Aardvark Therapeutics Launches $150 Million ATM Equity Program With Piper Sandler - TradingView
Tue, 24 Mar 2026
Raymond James reiterates Aardvark Therapeutics stock rating on dosing path - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 22 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 16.1 (%) |
| Held by Institutions | 58.8 (%) |
| Shares Short | 1,150 (K) |
| Shares Short P.Month | 1,380 (K) |
| EPS | -2.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.88 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -40.3 % |
| Return on Equity (ttm) | -64.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.88 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -54 (M) |
| Levered Free Cash Flow | -31 (M) |
| PE Ratio | -1.66 |
| PEG Ratio | 0 |
| Price to Book value | 0.99 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.96 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|